Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactitol is a synthetic disaccharide analogue of lactose, chemically classified as a sugar alcohol (polyol). It functions primarily as an osmotic laxative and a prebiotic. Upon oral administration, lactitol remains unabsorbed in the upper gastrointestinal tract and reaches the colon, where it is fermented by saccharolytic bacteria such as *Bifidobacterium* and *Lactobacillus* into short-chain fatty acids. This fermentation process acidifies the colonic contents, which facilitates the conversion of ammonia (NH3) into non-absorbable ammonium ions (NH4+), effectively trapping it in the gut for excretion. This mechanism is central to its use in treating hepatic encephalopathy. Additionally, the osmotic effect of lactitol and its fermentation products increases intraluminal pressure and water content, stimulating peristalsis to relieve constipation. Emerging research also indicates that lactitol may improve the prognosis of hepatocellular carcinoma by modulating the gut microbiota, specifically increasing the abundance of *Megasphaera* and *Bifidobacterium*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactitol.